7.95
-0.07 (-0.87%)
| Penutupan Terdahulu | 8.02 |
| Jumlah Dagangan | 12,312 |
| Harga / Jualan (P/S) | 0.410 |
| Harga / Buku (P/B) | 4.95 |
| Julat 52 Minggu |
| Margin Keuntungan | -63.52% |
| Margin Operasi (TTM) | -7.46% |
| EPS Cair (TTM) | -1.31 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -11.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 300.69% |
| Nisbah Semasa (MRQ) | 0.810 |
| Aliran Tunai Operasi (OCF TTM) | 3.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 5.51 M |
| Pulangan Atas Aset (ROA TTM) | -2.38% |
| Pulangan Atas Ekuiti (ROE TTM) | -138.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
| Medical Instruments & Supplies (Global) | Menaik | Bercampur | |
| Stok | Harvard Bioscience, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.57 |
|
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.27% |
| % Dimiliki oleh Institusi | 69.66% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |